



## Acquisition of own shares

### **BRUSSELS, Belgium, 28 June 2012 – 19:30 (CET) – regulated information –**

In application of art. 207 of the Royal Decree executing the Company Code, UCB SA/NV announces that, on Tuesday June 26th 2012, it sold 2.5 million UCB shares OTC for settlement on June 29th 2012 at a price of € 38.8302 per share. In combination with this spot transaction, also on Tuesday 26th June 2012, UCB SA/NV repurchased 2.5 million UCB shares OTC for settlement on 29th March 2013 at the same price per share, together a share swap transaction. The highest Brussels stock exchange price on June 26th 2012 was € 38.98.

In addition, UCB SA/NV has acquired 15,000 UCB shares on the Brussels stock exchange on the date and at the price indicated hereunder:

<u>Date</u>	<u>Price EUR</u>	<u>Amount</u>
21/06/2012	38.4007	15,000

These shares were distributed to the employees who have exercised share options that had been granted to them in the framework of existing Company's share option plans of which the detail is given in UCB annual report.

**UCB S.A. - Allée de la Recherche, 60 - 1070 Brussels - RPM 0403.053.608**

#### **For further information**

Antje Witte, Investor Relations, UCB  
T +32.2.559.9414, [antje.witte@uceb.com](mailto:antje.witte@uceb.com)

#### **About UCB**

UCB, Brussels, Belgium ([www.uceb.com](http://www.uceb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

#### **UCB Forward-looking statements**

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees. UCB is providing this



*information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.*

*There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.*

*Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.*